Published in Haematologica on May 16, 2006
Iron metabolism and the innate immune response to infection. Microbes Infect (2011) 1.32
Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr (2011) 1.14
Anemia and iron homeostasis in a cohort of HIV-infected patients in Indonesia. BMC Infect Dis (2011) 1.03
Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections. Proc Natl Acad Sci U S A (2014) 0.91
Nramp1 and Other Transporters Involved in Metal Withholding during Infection. J Biol Chem (2015) 0.90
Lentiviral Nef suppresses iron uptake in a strain specific manner through inhibition of Transferrin endocytosis. Retrovirology (2014) 0.84
Multivitamin supplementation improves haematologic status in children born to HIV-positive women in Tanzania. J Int AIDS Soc (2013) 0.81
Post-natal anaemia and iron deficiency in HIV-infected women and the health and survival of their children. Matern Child Nutr (2012) 0.76
Iron status and mortality in HIV infection. Haematologica (2006) 0.75
New equations to estimate GFR in children with CKD. J Am Soc Nephrol (2009) 11.48
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med (2005) 5.78
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med (2007) 3.96
The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol (2008) 3.60
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol (2013) 2.64
Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol (2004) 2.46
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis (2002) 2.29
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med (2011) 2.17
Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol (2004) 2.17
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS (2004) 1.94
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int (2012) 1.93
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA (2005) 1.86
Factors associated with use of dental services among HIV-infected and high-risk uninfected women. J Am Dent Assoc (2005) 1.79
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci (2003) 1.76
Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med (2002) 1.75
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol (2003) 1.74
Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med (2007) 1.72
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev (2011) 1.68
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS (2014) 1.66
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr (2007) 1.66
Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health (2004) 1.59
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
The New Face of Head and Neck Cancer: The HPV Epidemic. Oncology (Williston Park) (2015) 1.51
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50
Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. JPEN J Parenter Enteral Nutr (2002) 1.49
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol (2007) 1.48
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. Obstet Gynecol (2007) 1.46
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS (2016) 1.45
Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.44
Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer (2009) 1.42
Challenging the strategy of maternal age-based prenatal genetic counseling. JAMA (2006) 1.41
Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) (2009) 1.41
Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis (2007) 1.37
Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2002) 1.35
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35
C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr (2003) 1.35
The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction (2005) 1.32
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol (2014) 1.32
Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2005) 1.31